GSAC: AI 评分 65/100 — AI 分析 (4月 2026)

GelStat Corporation focuses on researching, developing, and marketing over-the-counter healthcare products. Their product line includes solutions for migraine relief, appetite suppression, energy supplementation, and sleep disorders.

Key Facts: AI Score: 65/100 Sector: Healthcare

公司概况

概要：

GelStat Corporation operates in the consumer healthcare sector, developing and marketing over-the-counter products like GelStat Migraine and Chews 2 Lose. With a small team and focus on non-prescription solutions, the company faces competition from larger generic drug manufacturers and established consumer health brands in a fragmented market.

GSAC是做什么的？

GelStat Corporation, headquartered in Palm City, Florida, is a consumer healthcare company engaged in the research, development, and marketing of over-the-counter (OTC) and other non-prescription consumer healthcare products. The company's portfolio includes GelStat Migraine, a patented product designed to provide pain relief from migraine headaches. Other products include Chews 2 Lose, an appetite suppressant gum intended as a diet aid; All Natural Speed, an energy supplement; and GelStat Sleep, a product formulated to alleviate sleep disorders and associated symptoms. GelStat Corporation distributes its products through a network of retailers, wholesalers, specialty distributors, and catalog merchandisers, utilizing both direct sales and external sales brokers. Founded with the aim of providing accessible consumer health solutions, GelStat Corporation has focused on developing and commercializing products that address common health concerns. The company's strategy involves identifying market needs and formulating products that can be sold directly to consumers without requiring a prescription. Despite its efforts, the company faces challenges in a competitive market dominated by larger players with greater resources and established brand recognition.

GSAC的投资论点是什么？

GelStat Corporation presents a high-risk, high-reward investment profile. The company's small market capitalization and limited resources make it vulnerable to market fluctuations and competitive pressures. A potential upside lies in the successful commercialization of its existing product line and the development of new OTC products. With a negative P/E ratio of -3.37 and a negative profit margin of -73.3%, the company's financial performance needs significant improvement. The company's beta of 1.26 indicates higher volatility compared to the market. Investors should carefully consider the risks associated with investing in a small, OTC-listed company with limited financial resources and a concentrated product portfolio.

GSAC在哪个行业运营？

GelStat Corporation operates within the competitive and highly regulated drug manufacturers - specialty & generic industry. This sector is characterized by intense competition, stringent regulatory requirements, and evolving consumer preferences. The market for over-the-counter (OTC) drugs and non-prescription healthcare products is substantial, driven by increasing consumer awareness and a desire for self-care solutions. However, companies like GelStat face challenges from larger, more established players with greater resources and broader distribution networks. The industry is also subject to regulatory scrutiny from agencies like the FDA, which impacts product development, manufacturing, and marketing activities.

Drug Manufacturers - Specialty & Generic

Healthcare

GSAC有哪些增长机遇？

Expansion of Product Line: GelStat can expand its product line by developing new OTC products targeting specific health concerns. The market for OTC products is vast, with opportunities in areas such as pain management, digestive health, and immune support. Successful development and launch of new products could drive revenue growth and increase market share. The timeline for this growth opportunity depends on the company's ability to secure funding for R&D and navigate regulatory approval processes.
Strategic Partnerships: GelStat can pursue strategic partnerships with larger pharmaceutical companies or distributors to expand its market reach and access new distribution channels. Collaborations could provide access to established sales networks and marketing resources, accelerating product adoption and revenue growth. The timeline for this growth opportunity depends on the company's ability to identify and secure suitable partners.
E-commerce Expansion: GelStat can invest in expanding its e-commerce presence to reach a wider customer base and capitalize on the growing trend of online shopping. Developing a user-friendly online platform and implementing effective digital marketing strategies could drive online sales and increase brand awareness. The timeline for this growth opportunity depends on the company's ability to invest in technology and digital marketing resources.
Geographic Expansion: GelStat can explore opportunities to expand its geographic reach by entering new markets outside of the United States. International expansion could provide access to new customer segments and diversify revenue streams. The timeline for this growth opportunity depends on the company's ability to navigate international regulatory requirements and establish distribution networks in new markets.
Focus on Niche Markets: GelStat can focus on developing and marketing products for niche markets with specific health needs. By targeting underserved segments of the population, the company can differentiate itself from larger competitors and build a loyal customer base. The timeline for this growth opportunity depends on the company's ability to identify and understand the needs of specific niche markets.

Market Cap of $0.00B reflects the company's small size and limited market presence.
P/E Ratio of -3.37 indicates the company is currently not profitable.
Profit Margin of -73.3% highlights significant challenges in achieving profitability.
Gross Margin of 70.3% suggests potential for profitability if operating expenses are managed effectively.
Beta of 1.26 indicates higher volatility compared to the overall market.

GSAC提供哪些产品和服务？

Researches and develops over-the-counter (OTC) healthcare products.
Markets and sells non-prescription consumer health products.
Offers GelStat Migraine for migraine pain relief.
Provides Chews 2 Lose appetite suppressant gum.
Sells All Natural Speed energy supplements.
Offers GelStat Sleep for relief from sleep disorders.
Distributes products through retailers, wholesalers, and distributors.

GSAC如何赚钱？

Develops and patents over-the-counter healthcare products.
Manufactures or outsources the production of its products.
Sells products directly to retailers, wholesalers, and distributors.
Generates revenue through product sales.

Retailers selling OTC healthcare products.
Wholesalers distributing healthcare products.
Specialty distributors focusing on specific product categories.
Consumers seeking non-prescription health solutions.

Patented GelStat Migraine formula provides some protection.
Established relationships with retailers and distributors.
Brand recognition among consumers seeking specific OTC solutions.

什么因素可能推动GSAC股价上涨？

Upcoming: Potential FDA approval for new OTC products in development.
Ongoing: Expansion of distribution network to new retailers and wholesalers.
Ongoing: Increased marketing efforts to drive product awareness and sales.

GSAC的主要风险是什么？

Potential: Intense competition from larger pharmaceutical companies.
Potential: Stringent regulatory requirements and potential product recalls.
Ongoing: Limited financial resources and potential need for additional funding.
Ongoing: Dependence on a few key products and potential for declining sales.
Potential: Product liability claims and associated legal expenses.

GSAC的核心优势是什么？

Patented GelStat Migraine formula.
Established distribution network.
Focus on over-the-counter products.
Gross margin of 70.3% indicates potential profitability.

GSAC的劣势是什么？

Small market capitalization.
Limited financial resources.
Negative profit margin.
High dependence on a few key products.

GSAC有哪些机遇？

Expansion of product line.
Strategic partnerships with larger companies.
E-commerce expansion.
Geographic expansion into new markets.

GSAC面临哪些威胁？

Intense competition from larger companies.
Stringent regulatory requirements.
Changing consumer preferences.
Potential product liability claims.

GSAC的竞争对手是谁？

Aoxing Pharmaceutical Company Inc — Focuses on narcotic and pain-relief pharmaceuticals. — (AOXG)
Cannawell PLC — Operates in the cannabis-based health and wellness sector. — (CWWBF)
FrontFour Capital Group LLC — Investment management firm, may hold positions in competing companies. — (FFNTF)
Green Power Fastening Technology, Inc. — Unclear overlap; potentially unrelated business. — (GPFT)
Larson Strategic Ventures, Inc. — Investment company, may hold positions in competing companies. — (LRSV)

Key Metrics

MoonshotScore: 65/100

Company Profile

CEO: Javier G. Acosta
Headquarters: Palm City, US
Employees: 2
Founded: 1996

AI Insight

AI analysis pending for GSAC

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does GelStat Corporation do?

GelStat Corporation is a consumer healthcare company that researches, develops, and markets over-the-counter (OTC) and non-prescription healthcare products. Its product line includes GelStat Migraine for migraine relief, Chews 2 Lose for appetite suppression, All Natural Speed for energy supplementation, and GelStat Sleep for sleep disorders. The company distributes these products through retailers, wholesalers, specialty distributors, and catalog merchandisers, targeting consumers seeking accessible and convenient health solutions. GelStat's business model focuses on identifying market needs and formulating products that can be sold directly to consumers without requiring a prescription.

What do analysts say about GSAC stock?

As of March 17, 2026, there is no available analyst coverage or consensus on GSAC stock. This is likely due to the company's small market capitalization, OTC listing, and limited financial resources. Investors should conduct their own independent research and due diligence before investing in GSAC, considering the risks and opportunities associated with the company's business model and financial condition. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, are not meaningful due to the company's current lack of profitability.

What are the main risks for GSAC?

GelStat Corporation faces several significant risks. These include intense competition from larger pharmaceutical companies with greater resources, stringent regulatory requirements and the potential for product recalls, limited financial resources and the need for additional funding, dependence on a few key products and the potential for declining sales, and potential product liability claims and associated legal expenses. Additionally, as an OTC-listed company, GSAC is subject to greater price volatility and liquidity risk compared to companies listed on major exchanges.